BIGBEAR
PHARMACEUTICAL
Enasidenib's innovative therapy offers a new treatment option for AML patients who are unresponsive to or experience relapse with conventional therapies.
AuthenticGuaranteeFast DeliveryPrivacy Enasidenib is an oral targeted therapy used for acute myeloid leukemia (AML) that exerts its effects by blocking isocitrate dehydrogenase-2 (IDH2).Mec···【More】
Update: 09 May,2026Source: BigbearViews: 104
Enasidenib is an oral medication used to treat acute myeloid leukemia (AML) in adult patients. Acute myeloid leukemia (AML) is a type of cancer that a···【More】
Update: 09 May,2026Source: BigbearViews: 119
August 1, 2017 — The U.S. Food and Drug Administration (FDA) has approved Enasidenib for the treatment of adult patients with relapsed or refractory a···【More】
Update: 08 May,2026Source: BigbearViews: 118
On November 29, 2018, the U.S. Food and Drug Administration (FDA) issued a warning stating that signs and symptoms of a life-threatening side effect k···【More】
Update: 08 May,2026Source: BigbearViews: 110
Enasidenib dosage and administration must strictly follow the doctor's instructions and be administered under the guidance of a professional physi···【More】
Update: 24 Mar,2026Source: BigbearViews: 113
Enasidenib is the first FDA-approved treatment for acute myeloid leukemia (AML) targeting IDH2 mutations, indicated for relapsed or refractory adult p···【More】
Update: 18 Mar,2026Source: BigbearViews: 117
Precautions for EnxidipineEnxidipine is used for relapsed or refractory acute myeloid leukemia (AML) with an IDH2 mutation. An FDA-approved diagnostic···【More】
Update: 18 Mar,2026Source: BigbearViews: 114
August 1, 2017 – The U.S. Food and Drug Administration (FDA) approved enasidenib for the treatment of adult patients with relapsed or refractory acute···【More】
Update: 10 Mar,2026Source: BigbearViews: 125
In addition to the expected therapeutic effects, some adverse reactions may occur when receiving enasidenib treatment. While not all side effects will···【More】
Update: 10 Mar,2026Source: BigbearViews: 114
On November 29, 2018, the U.S. Food and Drug Administration (FDA) warned that symptoms of differentiation syndrome, a life-threatening side effect of ···【More】
Update: 10 Mar,2026Source: BigbearViews: 110
On November 29, 2018, the U.S. Food and Drug Administration (FDA) warned that symptoms of differentiation syndrome, a life-threatening side effect of ···【More】
Update: 09 Mar,2026Source: BigbearViews: 109
Enasidenib was developed by Celgene in the United States and approved for marketing by the US FDA on August 1, 2017.Enasidenib (EnglishIndications)Ena···【More】
Update: 09 Mar,2026Source: BigbearViews: 110
Enasidenib is indicated for adult patients with relapsed or refractory acute myeloid leukemia (AML) who have been diagnosed with an isocitrate dehydro···【More】
Update: 09 Mar,2026Source: BigbearViews: 107
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
